1. Home
  2. RIGL vs NMAI Comparison

RIGL vs NMAI Comparison

Compare RIGL & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • NMAI
  • Stock Information
  • Founded
  • RIGL 1996
  • NMAI 2021
  • Country
  • RIGL United States
  • NMAI United States
  • Employees
  • RIGL N/A
  • NMAI N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • NMAI Investment Managers
  • Sector
  • RIGL Health Care
  • NMAI Finance
  • Exchange
  • RIGL Nasdaq
  • NMAI Nasdaq
  • Market Cap
  • RIGL 486.4M
  • NMAI 399.1M
  • IPO Year
  • RIGL 2000
  • NMAI N/A
  • Fundamental
  • Price
  • RIGL $21.81
  • NMAI $12.30
  • Analyst Decision
  • RIGL Buy
  • NMAI
  • Analyst Count
  • RIGL 5
  • NMAI 0
  • Target Price
  • RIGL $34.80
  • NMAI N/A
  • AVG Volume (30 Days)
  • RIGL 347.9K
  • NMAI 74.8K
  • Earning Date
  • RIGL 03-04-2025
  • NMAI 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • NMAI 13.14%
  • EPS Growth
  • RIGL N/A
  • NMAI N/A
  • EPS
  • RIGL 0.22
  • NMAI 0.64
  • Revenue
  • RIGL $157,374,000.00
  • NMAI N/A
  • Revenue This Year
  • RIGL $51.34
  • NMAI N/A
  • Revenue Next Year
  • RIGL $15.75
  • NMAI N/A
  • P/E Ratio
  • RIGL $98.50
  • NMAI $19.03
  • Revenue Growth
  • RIGL 21.65
  • NMAI N/A
  • 52 Week Low
  • RIGL $7.48
  • NMAI $10.60
  • 52 Week High
  • RIGL $29.82
  • NMAI $12.55
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 64.53
  • NMAI 55.19
  • Support Level
  • RIGL $17.28
  • NMAI $11.85
  • Resistance Level
  • RIGL $18.25
  • NMAI $12.25
  • Average True Range (ATR)
  • RIGL 1.37
  • NMAI 0.12
  • MACD
  • RIGL 0.65
  • NMAI 0.05
  • Stochastic Oscillator
  • RIGL 99.68
  • NMAI 98.89

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.

Share on Social Networks: